5,909 Shares in The Clorox Company $CLX Bought by Employees Retirement System of Texas

Employees Retirement System of Texas bought a new stake in The Clorox Company (NYSE:CLX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,909 shares of the company’s stock, valued at approximately $709,000.

Several other institutional investors and hedge funds have also bought and sold shares of CLX. OVERSEA CHINESE BANKING Corp Ltd purchased a new position in shares of Clorox in the first quarter worth approximately $369,000. HB Wealth Management LLC raised its position in Clorox by 7.9% in the first quarter. HB Wealth Management LLC now owns 4,951 shares of the company’s stock worth $729,000 after acquiring an additional 363 shares during the period. LPL Financial LLC boosted its stake in shares of Clorox by 12.7% during the 1st quarter. LPL Financial LLC now owns 334,041 shares of the company’s stock worth $49,188,000 after acquiring an additional 37,538 shares during the last quarter. Mackenzie Financial Corp grew its position in shares of Clorox by 8.4% during the 1st quarter. Mackenzie Financial Corp now owns 14,597 shares of the company’s stock valued at $2,149,000 after acquiring an additional 1,133 shares during the period. Finally, N.E.W. Advisory Services LLC purchased a new stake in shares of Clorox in the 1st quarter worth $120,000. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Stock Up 0.8%

Shares of CLX stock opened at $107.75 on Friday. The company’s fifty day simple moving average is $113.90 and its two-hundred day simple moving average is $121.57. The Clorox Company has a 52 week low of $98.20 and a 52 week high of $171.37. The stock has a market cap of $13.14 billion, a P/E ratio of 16.53, a PEG ratio of 0.92 and a beta of 0.52. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX) last issued its earnings results on Monday, November 3rd. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.07. The firm had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.41 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The business’s revenue was down 18.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.86 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Analysts predict that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 4.6%. The ex-dividend date of this dividend is Wednesday, January 28th. Clorox’s dividend payout ratio is 77.86%.

Insider Buying and Selling

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The stock was purchased at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the acquisition, the director owned 13,000 shares in the company, valued at $1,353,690. This trade represents a 44.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares in the company, valued at $6,711,475.38. This represents a 21.72% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.63% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. The Goldman Sachs Group lowered their target price on Clorox from $115.00 to $110.00 and set a “sell” rating on the stock in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Clorox in a research note on Tuesday, October 14th. JPMorgan Chase & Co. reduced their target price on shares of Clorox from $127.00 to $120.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Zacks Research downgraded shares of Clorox from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 28th. Finally, BNP Paribas Exane dropped their price target on shares of Clorox from $110.00 to $103.00 and set an “underperform” rating for the company in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $125.69.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.